Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Assets (2016 - 2025)

Veracyte (VCYT) has disclosed Assets for 14 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • Quarterly Assets rose 8.15% to $1.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 billion through Dec 2025, up 8.15% year-over-year, with the annual reading at $1.4 billion for FY2025, 8.15% up from the prior year.
  • Assets hit $1.4 billion in Q4 2025 for Veracyte, up from $1.4 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.4 billion in Q4 2025 to a low of $1.0 billion in Q1 2021.
  • Historically, Assets has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2021.
  • Biggest five-year swings in Assets: soared 300.19% in 2021 and later decreased 5.09% in 2022.
  • Year by year, Assets stood at $1.2 billion in 2021, then decreased by 2.64% to $1.2 billion in 2022, then decreased by 3.59% to $1.1 billion in 2023, then rose by 16.6% to $1.3 billion in 2024, then increased by 8.15% to $1.4 billion in 2025.
  • Business Quant data shows Assets for VCYT at $1.4 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.3 billion in Q2 2025.